GPC Biotech Schedules Conference Call on August 18th to Discuss First Half 2009 Financial Results

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich (Germany) and Princeton, N.J., August 11, 2009 -
GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that
it will hold a conference call on Tuesday, August 18, 2009 to discuss
its financial results for the second quarter and first half of 2009.
The results will be published on August 18th in advance of the call.

Participants may listen via live webcast, accessible through the GPC
Biotech Web site at www.gpc-biotech.com, or via telephone. A replay
will be available via the Web site following the live event. The
call, which will be conducted in English, will be held on August 18
at 15:00 CET/9:00 AM ET.

The dial-in numbers for the call are as follows:

Participants in Europe: 0049 (0) 69
667775756
0044 (0)20 3003 2666
Participants in the U.S.: 1-646-843-4608

About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on developing anti-cancer drugs. The Company currently has two
programs in clinical development: satraplatin, an oral platinum
compound, and RGB-286638, a multi-targeted protein kinase inhibitor.
The Company's shareholders have approved a merger agreement pursuant
to which the Company will combine its business with Agennix,
Incorporated, a privately held biotechnology company located in
Houston, Texas. Agennix is developing oral talactoferrin, a product
candidate that is currently in Phase 3 trials for non-small cell lung
cancer. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany) and has a wholly owned U.S. subsidiary in Princeton, New
Jersey. For additional information, please visit GPC Biotech's Web
site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC
Biotech. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this press release.
Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

For further information, please contact:

GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609-524-5884
usinvestors@gpc-biotech.com

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu

Hilda Juhasz
hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams, Vice President
Phone: +44 207 936 9325
lrigg@troutgroup.com

--- End of Message ---

GPC Biotech AG
Fraunhoferstr. 20 Martinsried Germany

WKN: 585150;
ISIN: DE0005851505; Index: CDAX, Prime All Share, TECH All Share,
DAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.